Table INF-18. Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 2001 to 2006, samples with average prevalence above 5 %

Country	Notes	2001	2002	2003	2004	2005	2006
Germany DT			4.6	3.9	4	5.3
Belgium SR	1	3.4	0	4.6	12.9
Sweden SP	1					5.5	6.4
Belgium SR	2			5.2	8.1	4.7
Belgium DT	3	5.9	6.2	5.6	6.1	7.1	5.7
Poland DT			6.9	8.9	4.5		8.9
Austria DT		5.8	3.6	6.8	9.4	11.9	7.1
Latvia DT		13.7	13.1	6.6
France SR	1	13.7	13.7	13.7
Italy DT		14.8	14.8	14.2	13.9	13.8	12.1
Germany SR	1		13	17	12
Portugal DT					19	20.2	20.2
Spain DT	1	37	36.2	34.5	31.9	36.1

Notes:

 Countries where the average of trend of available data are above 5 %.                

 Seroprevalence studies (SP); diagnostic testing (DT); unlinked anonymous testing (UAT); self-reported tests (SR).               

 Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary. 

 Data for Italy include non-IDUs and therefore may underestimate prevalence among IDUs.               

 Data for Belgium, Italy and Portugal are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment. Data for France, and part of the data for Belgium, are based on self-reported test results, which are less reliable than clinically documented tests. 

 1 - Sweden: data from Stockholm; France: data from 12 cities in France; Spain: National data, excluding communities of Madrid and La Rioja; Germany: Frankfurt; Belgium: data from French Community. 

 2 - Belgium: data from Wallon Region.               

 3 - Belgium: data from Antwerp.               

Related links:

 Statistical bulletin 2007: Figure INF-4.               

 See also ‘General notes for interpreting data’ on the Explanatory notes and help page, 

Sources:

 Reitox national focal points.               

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)